Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.
Clinic of Vascular and Internal Medicine, Dr Jan Biziel University Hospital No. 2 in Bydgoszcz, 85-168 Bydgoszcz, Poland.
Medicina (Kaunas). 2019 Jul 22;55(7):395. doi: 10.3390/medicina55070395.
Both in the pathogenesis of type 2 diabetes (DM 2) and Peripheral Arterial Disease (PAD), a vital role is played by endothelial dysfunction. Metabolic disorders found in DM 2 (hyperglycemia, insulin resistance), endothelial dysfunction, and increased inflammation lead to intensified atherothrombosis. The fibrinolysis system comprises a natural compensatory mechanism in case of hypercoagulability. The aim of this study was to assess concentrations of selected fibrinolysis parameters in the blood of patients with symptomatic PAD, including in particular concurrent DM 2 and other cardiovascular factors. In the group of 80 patients with PAD (27 F/53 M) and 30 healthy volunteers (10 F/20 M), the following parameters were measured: Concentrations of fibrinogen, tissue-Plasminogen Activator (t-PA Ag), Plasminogen Activator Inhibitor-1 (PAI-1 Ag), D-dimer, and platelet (PLT) count. In the blood of patients with PAD and concomitant DM 2 significantly higher concentrations of fibrinogen were found in comparison with patients with PAD and without diabetes ( = 0.044). No significant impact was observed in individuals with atherosclerotic complications (manifested by coronary artery disease, atherosclerosis of cerebral arteries) and selected cardiovascular risk factors (smoking, LDL and triglyceride concentrations, BP values) on the levels of t-PA, PAI-1, D-dimer, and PLT count. It was found that t-PA Ag and PAI-1 Ag values tended to rise along with a BMI increase in the subgroups of subjects (with normal body mass, overweight, and obesity), but no statistically significant differences were observed. However, two significant positive correlations were reported between t-PA Ag and BMI, as well as between PAI-1 Ag and BMI. Type 2 diabetes in peripheral arterial disease affects the concentration of fibrinogen causing its increase, which is connected with the inflammation and prothrombotic process in the course of both conditions. The concurrence of atherosclerosis of coronary or cerebral arteries, smoking, LDL and TG concentrations, and BP value do not have a significant impact on the levels of analyzed fibrinolysis parameters. A positive correlation between BMI and t-PA Ag and PAI-1 Ag concentrations needs to be supported in further studies on a larger number of overweight and obese patients.
在 2 型糖尿病(DM 2)和外周动脉疾病(PAD)的发病机制中,内皮功能障碍起着至关重要的作用。DM 2 中存在的代谢紊乱(高血糖、胰岛素抵抗)、内皮功能障碍和炎症增加导致动脉粥样硬化血栓形成加剧。纤溶系统是在高凝状态下的一种天然补偿机制。本研究旨在评估有症状的 PAD 患者血液中选定的纤溶参数浓度,特别是同时患有 DM 2 和其他心血管因素的患者。 在 80 名 PAD 患者(27 名女性/53 名男性)和 30 名健康志愿者(10 名女性/20 名男性)中,测量了以下参数:纤维蛋白原、组织型纤溶酶原激活物(t-PA Ag)、纤溶酶原激活物抑制剂-1(PAI-1 Ag)、D-二聚体和血小板(PLT)计数。 在患有 PAD 合并糖尿病的患者血液中,与患有 PAD 但无糖尿病的患者相比,纤维蛋白原浓度显著升高(=0.044)。在患有动脉粥样硬化并发症(表现为冠心病、脑动脉粥样硬化)和选定心血管危险因素(吸烟、LDL 和甘油三酯浓度、血压值)的个体中,t-PA、PAI-1、D-二聚体和 PLT 计数水平无显著影响。发现 t-PA Ag 和 PAI-1 Ag 值在亚组中(正常体重、超重和肥胖)随着 BMI 的增加而升高,但无统计学差异。然而,t-PA Ag 和 BMI 之间以及 PAI-1 Ag 和 BMI 之间存在两个显著的正相关关系。 在周围血管疾病中,2 型糖尿病会影响纤维蛋白原的浓度,导致其增加,这与两种疾病的炎症和促血栓形成过程有关。冠状动脉或脑动脉粥样硬化、吸烟、LDL 和 TG 浓度以及血压值的并存对分析的纤溶参数水平没有显著影响。需要在对更多超重和肥胖患者进行的进一步研究中证实 BMI 与 t-PA Ag 和 PAI-1 Ag 浓度之间的正相关关系。